Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.

Separating the winners from the value traps is a tough challenge, and that’s where StockStory comes in. Our job is to find you high-quality companies that will stand the test of time. Keeping that in mind, here are three value stocks facing an uphill battle and some other investments you should look into instead.

Xponential Fitness (XPOF)

Forward P/E Ratio: 8.6x

Owner of Club Pilates, Stretch Lab, BFT and Pure Barre, Xponential Fitness (NYSE: XPOF) is a boutique fitness brand offering diverse and specialized exercise experiences.

Why Should You Sell XPOF?

1. Sales trends were unexciting over the last five years as its 19.5% annual growth was below the typical consumer discretionary company
2. Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
3. 5× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings

At $4.90 per share, Xponential Fitness trades at 8.6x forward P/E. Dive into our free research report to see why there are better opportunities than XPOF.

American Airlines (AAL)

Forward P/E Ratio: 11.2x

One of the ‘Big Four’ airlines in the US, American Airlines (NASDAQ: AAL) is a major global air carrier that serves both business and leisure travelers through its domestic and international flights.

Why Are We Bearish on AAL?

1. Sluggish trends in its revenue passenger miles suggest customers aren’t adopting its solutions as quickly as the company hoped
2. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

American Airlines’s stock price of $14.85 implies a valuation ratio of 11.2x forward P/E. To fully understand why you should be careful with AAL, check out our full research report (it’s free).

Integra LifeSciences (IART)

Forward P/E Ratio: 7.2x

Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.

Why Is IART Risky?

1. Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
2. Incremental sales over the last five years were much less profitable as its earnings per share fell by 4.6% annually while its revenue grew
3. 5× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly

Integra LifeSciences is trading at $18.33 per share, or 7.2x forward P/E. Read our free research report to see why you should think twice about including IART in your portfolio.

Stocks We Like More

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.